Related Experiment Video
Updated: Dec 21, 2025

Author Spotlight: Combining Proximity Ligand Assay with Gamma-H2AX Staining to Characterize Protein Interactions in DNA Damage Response
Published on: August 2, 2024
Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1
Isabel Freund1,2, Stephanie Hehlgans1, Daniel Martin1
1Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Abstract:
NIMA (never-in-mitosis gene A)-related kinase 1 (Nek1) is shown to impact on different cellular pathways such as DNA repair, checkpoint activation, and apoptosis. Its role as a molecular target for radiation sensitization of malignant cells, however, remains elusive. Stably transduced doxycycline (Dox)-inducible Nek1 shRNA HeLa cervix and siRNA-transfected HCT-15 colorectal carcinoma cells were irradiated in vitro and 3D clonogenic radiation survival, residual DNA damage, cell cycle distribution, and apoptosis were analyzed. Nek1 knockdown (KD) sensitized both cell lines to ionizing radiation following a single dose irradiation and more pronounced in combination with a 6 h fractionation (3 × 2 Gy) regime. For preclinical analyses we focused on cervical cancer. Nek1 shRNA HeLa cells were grafted into NOD/SCID/IL-2Rγc-/- (NSG) mice and Nek1 KD was induced by Dox-infused drinking water resulting in a significant cytostatic effect if combined with a 6 h fractionation (3 x 2 Gy) regime. In addition, we correlated Nek1 expression in biopsies of patients with cervical cancer with histopathological parameters and clinical follow-up. Our results indicate that elevated levels of Nek1 were associated with an increased rate of local or distant failure, as well as with impaired cancer-specific and overall survival in univariate analyses and for most endpoints in multivariable analyses. Finally, findings from The Cancer Genome Atlas (TCGA) validation cohort confirmed a significant association of high Nek1 expression with a reduced disease-free survival. In conclusion, we consider Nek1 to represent a novel biomarker and potential therapeutic target for drug development in the context of optimized fractionation intervals.
Insights
NIMA (never-in-mitosis gene A)-related kinase 1 (Nek1) knockdown sensitizes cancer cells to radiation therapy and may serve as a predictive biomarker for treatment response in cervical cancer patients. Targeting Nek1 could improve radiation therapy outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Radiation Oncology
Background:
- NIMA (never-in-mitosis gene A)-related kinase 1 (Nek1) influences DNA repair, cell cycle checkpoints, and apoptosis.
- The potential of Nek1 as a molecular target for enhancing radiation sensitivity in malignant cells is not well understood.
Purpose of the Study:
- To investigate the role of Nek1 in cellular response to ionizing radiation.
- To evaluate Nek1 as a potential biomarker for predicting treatment outcomes in cervical cancer.
Main Methods:
- Utilized doxycycline-inducible Nek1 shRNA in HeLa and siRNA in HCT-15 cells for knockdown studies.
- Assessed radiosensitivity, DNA damage, cell cycle, and apoptosis in vitro.
- Conducted preclinical studies in NSG mice xenograft models of cervical cancer.
- Correlated Nek1 expression in patient biopsies with clinical data and TCGA cohort.
Main Results:
- Nek1 knockdown (KD) sensitized both cell lines to ionizing radiation, particularly with fractionated doses.
- Nek1 KD combined with fractionated radiation showed a significant cytostatic effect in preclinical cervical cancer models.
- Elevated Nek1 expression in cervical cancer patients correlated with increased treatment failure and reduced survival.
- TCGA data validated the association between high Nek1 expression and decreased disease-free survival.
Conclusions:
- Nek1 plays a crucial role in cellular response to radiation therapy.
- Nek1 is a potential predictive biomarker for radiation therapy response in cervical cancer.
- Targeting Nek1 may offer a therapeutic strategy to improve outcomes with optimized radiation fractionation.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Nucleotide Excision Repair

